

---

## Purpose

This document provides you with key information about this investment product. It is not marketing material. The information is required by law to help you understand the nature, risks, costs, potential gains and losses of this product and to help you compare it with other products.

---

## Product

**Name of Product:** Invesco China Health Care Equity Fund Z (USD)-Acc Shares

**PRIP Manufacturer:** Invesco Management S.A., part of the Invesco Group

**ISIN:** LU2305833829

**Website:** <http://www.invescomanagementcompany.lu>

Call +353 1 439 8100 for more information.

The Commission de Surveillance du Secteur Financier (CSSF) is responsible for supervising Invesco Management S.A. in relation to this Key Information Document.

This PRIIP is authorised in Luxembourg.

Invesco Management S.A. is authorised in Luxembourg and regulated by the Commission de Surveillance du Secteur Financier (CSSF).

This Key Information Document is accurate as at 01 January 2023.

---

## What is this product?

### Type

The Fund is a sub-fund of Invesco Funds (the "Umbrella Fund"), an open-ended umbrella investment fund established under the laws of Luxembourg and harmonised under the EU Council Directive 2009/65/EC relating to Undertakings for Collective Investment in Transferable Securities (UCITS).

### Term

The Fund does not have a maturity date and may only be terminated in accordance with the terms set out in the Prospectus.

### Objectives

- The objective of the Fund is to achieve long term capital growth.
- The Fund invests in Chinese healthcare companies listed on the Shanghai or Shenzhen Stock Exchanges, traded via Stock Connect as well as those listed or traded elsewhere, included Qualified Foreign Investors (QFI).
- The Fund invests in companies which are attractively valued and demonstrate sustainable growth, along with a strong business model and sound balance sheet.
- For the purposes of the Fund, healthcare companies include (but are not limited to) companies in the sectors of pharmaceuticals, biotechnology, healthcare services and medical technology and supplies.
- The Fund may use derivatives (complex instruments) to manage the Fund more efficiently, with the aim of reducing risk, reducing costs and/or generating additional capital or income.
- The Fund is actively managed and is not constrained by its benchmark, MSCI China A Onshore Health Care Index, which is used for comparison purposes. However, as the benchmark is a suitable proxy for the investment strategy, it is likely that some of the Fund's holdings are also components of the benchmark. As an actively managed fund, this overlap will change and this statement may be updated from time to time.
- The Fund has broad discretion over portfolio construction and therefore securities, weightings and risk characteristics will differ. As a result, it is expected that over time the risk return characteristics of the Fund may diverge materially to the benchmark.
- Please refer to the past performance of the Fund published on the website of Invesco Management S.A, where a benchmark will be displayed if relevant.
- The Fund promotes environmental, social and governance (ESG) criteria as covered under Article 8 of the Regulation (EU) 2019/2088 on sustainability-related disclosures in the financial services sector.
- You can buy and sell shares in the Fund on any Dealing Day (as defined in the Prospectus).
- Any income from your investment will be reinvested.


### Intended Retail Investor

The Fund is intended for investors aiming for long term capital growth, who may not have specific financial expertise but are able to make an informed investment decision based on this document and the Prospectus, and have a risk appetite consistent with the risk indicator displayed below and understand that there is no capital guarantee or protection (100% of capital is at risk).

Depository: The Bank of New York Mellon SA/NV, Luxembourg Branch. There may be tax implications in your country of residence and/or origin. Invesco Management S.A. may be held liable solely on the basis of any statement contained in this document that is misleading, inaccurate or inconsistent with the relevant parts of the Prospectus. The Umbrella Fund is structured by having different sub-funds. The assets and liabilities of each sub-fund are segregated by Luxembourg Law. The assets of the Fund will not be available to meet the liabilities of another sub-fund within the Umbrella Fund. You are not entitled to switch from this Fund to another fund. Please refer to the Prospectus for more information. This key information document describes one share class. More share classes may be available for this Fund. You can find more information on the Invesco local websites. You can check the latest price for the Share Class on our website and on Reuters, Bloomberg and Morningstar. Information on the up-to-date remuneration policy of Invesco Management S.A., including but not limited to, a description of how remuneration and benefits are calculated and the identity of persons responsible for awarding the remuneration and benefits, including the composition of the remuneration committee, is available at [www.invescomanagementcompany.lu](http://www.invescomanagementcompany.lu) and a copy can be obtained, free of charge, from the Management Company. The Prospectus and the annual and semi-annual reports can be obtained free of charge from the Fund's Registrar and Transfer Agent, The Bank of New York SA/NV, Luxembourg Branch, BP 648, L-2016 Luxembourg, by emailing [queries@invesco.com](mailto:queries@invesco.com) or on our website: [www.invesco.com](http://www.invesco.com). The Prospectus is available in English, French, Spanish, Italian and German and the reports in English and German. The Prospectus and the reports are prepared for the entire Umbrella Fund.

## What are the risks and what could I get in return?

### Risk Indicator



The risk indicator assumes that you keep the product for 5 years. The actual risk can vary significantly if you cash in at an early stage and you may get back less.

The summary risk indicator is a guide to the level of risk of this product compared to other products. It shows how likely it is that the product will lose money because of movements in the markets or because we are not able to pay you.

We have classified this product as 5 out of 7, which is a medium-high risk class.

This rates the potential losses from future performance at a medium-high level, and poor market conditions will likely impact the capacity of the PRIIPs manufacturer to pay you.

**Be aware of currency risk. In some circumstances, you may receive payments in a different currency from your local currency, so the final return you will get may depend on the exchange rate between the two currencies. This risk is not considered in the indicator shown above.**

Other risks such as Liquidity, Stock Connect, QFI, ESG and Derivatives risks may impact the Fund. Please refer to the Prospectus for more details.

This product does not include any protection from future market performance so you could lose some or all of your investment.

### Performance Scenarios

The figures shown include all the costs of the product itself, but may not include all the costs that you pay to your advisor or distributor. The figures do not take into account your personal tax situation, which may also affect how much you get back.

What you will get from this product depends on future market performance. Market developments in the future are uncertain and cannot be accurately predicted.

The unfavourable, moderate, and favourable scenarios shown are illustrations using the worst, average, and best performance of the product and a suitable benchmark over the last 10 years. Markets could develop very differently in the future.

The stress scenario shows what you might get back in extreme market circumstances.

The unfavourable scenario occurred for an investment in the benchmark between June 2021 and October 2022.

The moderate scenario occurred for an investment in the benchmark between March 2017 and March 2022.

The favourable scenario occurred for an investment in the benchmark between November 2012 and November 2017.

### Recommended holding period: 5 years

#### Example Investment: USD 10,000

Scenarios		If you exit after 1 year	If you exit after 5 years
Minimum	There is no minimum guaranteed return. You could lose some or all of your investment.		
Stress	What you might get back after costs	2,750 USD	1,570 USD
	Average return each year	-72.51 %	-30.97 %
Unfavourable	What you might get back after costs	4,580 USD	4,130 USD
	Average return each year	-54.24 %	-16.23 %
Moderate	What you might get back after costs	9,630 USD	9,780 USD
	Average return each year	-3.72 %	-0.44 %
Favourable	What you might get back after costs	17,890 USD	16,220 USD
	Average return each year	78.90 %	10.15 %

### What happens if Invesco Management S.A. is unable to pay out?

The assets of the Fund are segregated from those of Invesco Management S.A. In addition, The Bank of New York Mellon SA/NV, Luxembourg Branch, as the depositary of Invesco Funds (the "Depositary"), is responsible for the safekeeping of the assets of the Fund. To that effect, if Invesco Management S.A. defaults, there will be no direct financial impact on the Fund. In addition, the Fund's assets shall be segregated from the Depositary's assets, which limits the risk for the Fund suffering some loss in case of default of the Depositary. As a shareholder in the Fund, there is no compensation or guarantee scheme in place.

### What are the costs?

**The person advising on or selling you this product may charge you other costs. If so, this person will provide you with information about these costs and how they affect your investment.**

#### Costs over time

The tables show the amounts that are taken from your investment to cover different types of costs. These amounts depend on how much you invest and how long you hold the product. The amounts shown here are illustrations based on an example investment amount and different possible investment periods.

We have assumed:

- In the first year, you would get back the amount that you invested (0 % annual return). For the other holding periods we have assumed the product performs as shown in the moderate scenario.

- USD 10,000 is invested.

	If you exit after 1 year	If you exit after 5 years
Total costs	756 USD	1,900 USD
Annual cost impact (*)	7.6%	3.6% each year

(\*) This illustrates how costs reduce your return each year over the holding period. For example it shows that if you exit at the recommended holding period your average return per year is projected to be 3.2% before costs and -0.4% after costs.

## Composition of costs

<b>One-off costs upon entry or exit</b>		<b>If you exit after 1 year</b>
Entry costs	Not exceeding 5 % of the amount you pay when entering this investment. The person selling you the product will inform you of the actual charge	Up to 500 USD
Exit costs	We do not charge an exit fee for this product, but the person selling you the product may do so.	0 USD
<b>Ongoing costs [taken each year]</b>		
Management fees and other administrative or operating costs	1.09% of the value of your investment per year. This is an estimate based on actual costs over the last year.	109 USD
Transaction costs	1.47% of the value of your investment per year. This is an estimate of the costs incurred when we buy and sell the underlying investments for the product. The actual amount will vary depending on how much we buy and sell.	147 USD
<b>Incidental costs taken under specific conditions</b>		
Performance fees	There is no performance fee for this product.	0 USD

## How long should I hold it and can I take money out early?

### Recommended holding period: 5 years

We have selected 5 years as the Fund invests for the long term.

You can sell your shares in the Fund on any Dealing Day as defined in the Prospectus.

If you sell some or all of your investment before 5 years the Fund will be less likely to achieve its objectives, however, you will not incur any additional costs by doing so.

### How can I complain?

If you wish to make a complaint about the Fund, Invesco Management S.A. or any person advising or selling the Fund, you should write to The Bank of New York SA/NV, Luxembourg Branch, BP 648, L2016 Luxembourg or Invesco Management S.A., at 37a Avenue J.F. Kennedy, L-1855, Luxembourg, or send an e-mail to [queries@invesco.com](mailto:queries@invesco.com).

In the event that you are not satisfied with our response to your complaint you can refer the matter to the Luxembourg Supervisory Authority by writing to the Commission de Surveillance du Secteur Financier (CSSF) at 283 route d'Arlon, L-2991, Luxembourg, by email at [reclamation@cssf.lu](mailto:reclamation@cssf.lu), or by any other means accepted by the CSSF.

For more information, please refer to the Investor Complaint Handling Information Notice at [www.invescomanagementcompany.lu](http://www.invescomanagementcompany.lu).

### Other relevant information

Other information on the Fund is made available to shareholders on [www.invescomanagementcompany.lu](http://www.invescomanagementcompany.lu) and through the Invesco local websites.

Past performance over the last 10 years are made available at <https://www.invesco.com/emea/en/priips.html>.

Previous performance scenarios over the last year are made available at <https://www.invesco.com/emea/en/priips.html>.

- In Switzerland, the Prospectus, the key information documents, the articles of incorporation of the Umbrella Fund as well as the annual and interim reports of the Umbrella Fund can be obtained free of charge from the representative in Switzerland, Invesco Asset Management (Switzerland) Ltd., Talacker 34, CH-8001 Zurich. The paying agent of the Umbrella Fund in Switzerland is BNP PARIBAS, Paris, Zurich Branch, Selnaustrasse 16, CH-8002 Zurich.